Sertraline

Summary

Sertraline (CHEMBL809) is an approved small-molecule antidepressant (ATC N06AB06) targeting SLC6A4; indicated across 31 conditions including major depressive disorder and depressive disorder.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: N06AB06
• Targets: 1 (SLC6A4)
• Indications: 31 conditions
• Clinical trials: 248
• Chemistry: 306.2 Da · C17H17Cl2N

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL809
Name	Sertraline
Type	Small molecule
Max phase	4
FDA approved	yes
PubChem CID	68617
ChEBI	CHEBI:9123
ATC	N06AB06
Molecular formula	C17H17Cl2N
Molecular weight	306.2
InChIKey	VGKDLMBJGBXTGI-SJCJKPOMSA-N

SMILES: CN[C@H]1CC[C@H](C2=CC=CC=C12)C3=CC(=C(C=C3)Cl)Cl

IUPAC name: (1S,4S)-4-(3,4-dichlorophenyl)-N-methyl-1,2,3,4-tetrahydronaphthalen-1-amine

ChEBI definition: A member of the class of tetralins that is tetralin which is substituted at positions 1 and 4 by a methylamino and a 3,4-dichlorophenyl group, respectively (the S,S diastereoisomer). A selective serotonin-reuptake inhibitor (SSRI), it is administered orally as the hydrochloride salt as an antidepressant for the treatment of depression, obsessive-compulsive disorder, panic disorder and post-traumatic stress disorder.

Pharmacological roles (ChEBI): antidepressant, serotonin uptake inhibitor.

Also known as: Sertralina, Sertraline, sertraline, SID29215139, SID49665783, SID90341218, SID26753299, SID50105682, SID50105683, SID50105684, SID50105685, SERTRALINE

Parent form; salt/anhydrous children: CHEMBL1709

Patent coverage: 14,042 distinct patent families (51,342 SureChEMBL compound mentions), from 4 matched compound structure(s). One matched structure accounts for 51,208 (100%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Primary targets (GtoPdb curated mechanism): the Cancer dependency column is the DepMap CRISPR fitness signal (% of screened cell lines dependent on the target).

Gene	Target	Action	pAffinity	Cancer dependency	UniProt
SLC6A4	SERT	Inhibition	9.1	0.7%	P31645

Broader ChEMBL bioactivity targets: 61 (assay-derived). Sample: 4’-phosphopantetheinyl transferase ffp, NPC intracellular cholesterol transporter 1, Ras-related protein Rab-9A, Histone-lysine N-methyltransferase 2A, Vasopressin V2 receptor, Muscarinic acetylcholine receptor M4, 5-hydroxytryptamine receptor 2B, Alpha-2A adrenergic receptor, 5-hydroxytryptamine receptor 3A, Alpha-2C adrenergic receptor, Voltage-dependent L-type calcium channel subunit alpha-1C, Alpha-2B adrenergic receptor, Sodium channel protein type 5 subunit alpha, Beta-lactamase, Muscarinic acetylcholine receptor M5, Estrogen receptor, Menin/Histone-lysine N-methyltransferase MLL, Muscarinic acetylcholine receptor M2, Beta-1 adrenergic receptor, 5-hydroxytryptamine receptor 1A.

Bioactivity

ChEMBL activities: 83 potent at pChembl ≥ 5 of 121 total. Top 100 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
SLC6A4	10.12	Ki	0.07	nM	CHEMBL_ACT_7811653
SLC6A4	9.85	IC50	0.14	nM	CHEMBL_ACT_7811652
SLC6A4	9.72	IC50	0.19	nM	CHEMBL_ACT_22850859
SLC6A4	9.54	Kd	0.29	nM	CHEMBL_ACT_163262
P31652	9.07	Ki	0.85	nM	CHEMBL_ACT_720331
SLC6A4	8.7	AC50	2	nM	CHEMBL_ACT_25150033
SLC6A4	8.52	IC50	3	nM	CHEMBL_ACT_1694302
SLC6A4	8.52	IC50	3	nM	CHEMBL_ACT_5129149
P31652	8.47	Ki	3.4	nM	CHEMBL_ACT_163266
SLC6A3	7.6	Kd	25	nM	CHEMBL_ACT_163264
SLC6A3	7.59	Ki	25.8	nM	CHEMBL_ACT_7809507
SIGMAR1	7.53	Ki	29.3	nM	CHEMBL_ACT_7811655
SLC6A3	7.49	IC50	32.4	nM	CHEMBL_ACT_7809506
SIGMAR1	7.24	Ki	57	nM	CHEMBL_ACT_12180086
Q9R0C9	7.24	Ki	57	nM	CHEMBL_ACT_22850841
P31652	7.22	IC50	60	nM	CHEMBL_ACT_1270449
SIGMAR1	7.16	IC50	69.7	nM	CHEMBL_ACT_7811654
P23977	7.11	Ki	78.3	nM	CHEMBL_ACT_720329
ADRA2B	7.08	Ki	82.8	nM	CHEMBL_ACT_7809433
ADRA2A	6.96	Ki	108.3	nM	CHEMBL_ACT_7809431
ADRA2B	6.74	IC50	181.4	nM	CHEMBL_ACT_7809432
SLC6A3	6.66	AC50	219.4	nM	CHEMBL_ACT_25123641
P23977	6.58	Ki	260	nM	CHEMBL_ACT_163268
ADRA2A	6.54	IC50	288.8	nM	CHEMBL_ACT_7807426
SLC6A3	6.51	IC50	310	nM	CHEMBL_ACT_1694303
SLC6A3	6.51	IC50	310	nM	CHEMBL_ACT_5129213
CYP2C19	6.51	IC50	310	nM	CHEMBL_ACT_5130476
CHRM1	6.51	Ki	310.2	nM	CHEMBL_ACT_7809561
P23977	6.5	IC50	320	nM	CHEMBL_ACT_1279361
P15823	6.47	Ki	334.9	nM	CHEMBL_ACT_7807423
OPRK1	6.46	AC50	346.4	nM	CHEMBL_ACT_25129147
CHRM5	6.44	Ki	364.5	nM	CHEMBL_ACT_7809569
CHRM4	6.43	Ki	366.9	nM	CHEMBL_ACT_7809567
SLC6A2	6.38	Kd	420	nM	CHEMBL_ACT_163263
P31652	6.34	IC50	460	nM	CHEMBL_ACT_1279362
Q01827	6.31	AC50	490.7	nM	CHEMBL_ACT_25197349
CHRM5	6.29	IC50	507.3	nM	CHEMBL_ACT_7809568
HTR2C	6.25	Ki	567.3	nM	CHEMBL_ACT_7811645
P15823	6.22	IC50	605	nM	CHEMBL_ACT_7807422
ADRA2C	6.19	Ki	650.5	nM	CHEMBL_ACT_7809435
HTR2A	6.11	Ki	783.1	nM	CHEMBL_ACT_7811641
CYP3A4	6.1	IC50	800	nM	CHEMBL_ACT_5129318
SLC6A2	6.08	IC50	825	nM	CHEMBL_ACT_1694304
SLC6A2	6.08	IC50	825	nM	CHEMBL_ACT_5129181
SLC6A2	6.01	IC50	984.8	nM	CHEMBL_ACT_7809442
SLC6A2	6.01	Ki	976.6	nM	CHEMBL_ACT_7809443
CHRM2	6.01	Ki	984	nM	CHEMBL_ACT_7809563
CYP2C19	6	IC50	1000	nM	CHEMBL_ACT_7809488
HTR2C	5.96	IC50	1083	nM	CHEMBL_ACT_7811644
P23977	5.89	IC50	1300	nM	CHEMBL_ACT_1270448
CHRM1	5.89	IC50	1288	nM	CHEMBL_ACT_7809560
CYP2D6	5.85	IC50	1400	nM	CHEMBL_ACT_5129304
KCNH2	5.71	AC50	1930	nM	CHEMBL_ACT_25117404
HTR2B	5.67	Ki	2160	nM	CHEMBL_ACT_7811643
P22002	5.64	IC50	2310	nM	CHEMBL_ACT_15373289
P22002	5.58	IC50	2600	nM	CHEMBL_ACT_15777541
CHRM4	5.58	IC50	2631	nM	CHEMBL_ACT_7809566
CHRM2	5.56	IC50	2768	nM	CHEMBL_ACT_7809562
HTR2A	5.56	IC50	2741	nM	CHEMBL_ACT_7811640
CYP2D6	5.54	IC50	2880	nM	CHEMBL_ACT_15450959
ADRA2B	5.54	AC50	2900	nM	CHEMBL_ACT_25143397
HTR2B	5.47	IC50	3394	nM	CHEMBL_ACT_7811642
ADRA1A	5.46	AC50	3448	nM	CHEMBL_ACT_25137748
MEN1	5.45	Potency	3548	nM	CHEMBL_ACT_4575511
ADRA2C	5.4	AC50	3957	nM	CHEMBL_ACT_25147562
MC5R	5.37	Ki	4313	nM	CHEMBL_ACT_7809557
HTR2A	5.36	AC50	4350	nM	CHEMBL_ACT_25173508
ADRA2C	5.35	IC50	4477	nM	CHEMBL_ACT_7809434
MC5R	5.34	IC50	4598	nM	CHEMBL_ACT_7809556
CACNA1C	5.3	AC50	5000	nM	CHEMBL_ACT_25159061
Q5U3Y7	5.28	Ki	5297	nM	CHEMBL_ACT_22850815
OPRM1	5.21	AC50	6200	nM	CHEMBL_ACT_25146746
SLC6A2	5.17	AC50	6702	nM	CHEMBL_ACT_25144693
KCNH2	5.17	Ki	6814	nM	CHEMBL_ACT_7811599
ADRA1A	5.12	AC50	7550	nM	CHEMBL_ACT_25217856
HTR2B	5.12	AC50	7502	nM	CHEMBL_ACT_25227235
KMT2A	5.1	Potency	7943	nM	CHEMBL_ACT_3789382
MC3R	5.09	AC50	8126	nM	CHEMBL_ACT_25183088
ADRB1	5.08	AC50	8343	nM	CHEMBL_ACT_25121474
HTR2C	5.08	AC50	8378	nM	CHEMBL_ACT_25131504
KCNH2	5.08	IC50	8317	nM	CHEMBL_ACT_7811598
CHRM1	5.01	AC50	9800	nM	CHEMBL_ACT_25135136
HTR2A	5.01	AC50	9800	nM	CHEMBL_ACT_25224888

Target pathways

Aggregated over 1 target gene(s): SLC6A4.

Top Reactome pathways

5 total, by targets touching each:

Pathway	Targets	Genes
Neurotransmitter clearance	1	SLC6A4
Transmission across Chemical Synapses	1	SLC6A4
Neuronal System	1	SLC6A4
Serotonin clearance from the synaptic cleft	1	SLC6A4
SLC-mediated transport of neurotransmitters	1	SLC6A4

Dominant GO biological processes

GO term	Targets
response to hypoxia	1
neurotransmitter transport	1
amino acid transport	1
response to nutrient	1
memory	1
circadian rhythm	1
response to xenobiotic stimulus	1
response to toxic substance	1
positive regulation of gene expression	1
positive regulation of serotonin secretion	1
obsolete monoamine transport	1
negative regulation of cerebellar granule cell precursor proliferation	1
negative regulation of synaptic transmission, dopaminergic	1
response to estradiol	1
sodium ion transmembrane transport	1

Indications & clinical

Indications

2 approved indications. FDA phase 4, plus an anticancer drug’s labelled cancer uses (which ChEMBL often logs at phase 3).

Indication	Phase	MONDO	EFO
major depressive disorder	4	MONDO:0002009	MONDO:0002009
depressive disorder	4	MONDO:0002050	MONDO:0002050

25 diseases in clinical trials (phase 1–3, investigational — not approved indications). Highest ChEMBL trial phase per disease; a non-cancer approved use is occasionally logged at phase 3 here.

Disease (in trials)	Phase	MONDO	EFO
post-traumatic stress disorder	3	MONDO:0005146	EFO:0001358
autism	3	MONDO:0005260	EFO:0003758
obsessive-compulsive disorder	3	MONDO:0008114	EFO:0004242
insomnia	3	MONDO:0013600	EFO:0004698
anxiety	3	MONDO:0011918	EFO:0005230
Cryptococcal meningitis	3	MONDO:0005723	EFO:0007228
social phobia	3	MONDO:0001247	EFO:1001917
dementia	3	MONDO:0001627	HP:0000726
generalized anxiety disorder	3	MONDO:0001942	EFO:1001892
bipolar disorder	3	MONDO:0004985	MONDO:0004985
cocaine dependence	2	MONDO:0005186	EFO:0002610
autism spectrum disorder	2	MONDO:0005258	EFO:0003756
drug dependence	2	MONDO:0005303	EFO:0003890
mood disorder	2	MONDO:0005371	EFO:0004247
panic disorder	2	MONDO:0005383	EFO:0004262
coccidioidomycosis	2	MONDO:0005706	EFO:0007211
postpartum depression	2	MONDO:0005929	EFO:0007453
alcohol abuse	2	MONDO:0002046	MONDO:0002046
brain injury	2	MONDO:0043510	MONDO:0043510
fragile X syndrome	2	MONDO:0010383	MONDO:0010383
myelodysplastic syndrome	1	MONDO:0018881	EFO:0000198
acute myeloid leukemia	1	MONDO:0018874	EFO:0000222
glioblastoma	1	MONDO:0018177	EFO:0000519
obesity disorder	1	MONDO:0011122	EFO:0001073
hepatitis C virus infection	1	MONDO:0005231	EFO:0003047

4 further indication records had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 248.

Phase distribution

Phase	Trials
PHASE4	76
Not specified	56
PHASE3	39
PHASE2	37
PHASE1	19
PHASE2/PHASE3	11
PHASE1/PHASE2	9
EARLY_PHASE1	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT04221997	PHASE4	RECRUITING	Trial With the Treatment of Sertraline in Youth With Generalized, Separation and/or Social Anxiety Disorders.
NCT05273996	PHASE4	ACTIVE_NOT_RECRUITING	Predictors of Cognitive Outcomes in Geriatric Depression
NCT05892744	PHASE4	RECRUITING	Establishing Multimodal Brain Biomarkers for Treatment Selection in Depression
NCT07011693	PHASE4	NOT_YET_RECRUITING	Switching Medication and Augmentation Strategies for SSRI-Resistant Adolescent Depression（SMART-I)
NCT00000378	PHASE4	COMPLETED	Antidepressant Treatment of Melancholia in Late Life
NCT00004554	PHASE4	COMPLETED	Sertraline for Alcohol Dependence and Depression
NCT00009191	PHASE4	COMPLETED	The Depression in Alzheimer’s Disease Study (DIADS)
NCT00021528	PHASE4	COMPLETED	Sequenced Treatment Alternatives to Relieve Depression (STAR*D)
NCT00050804	PHASE4	COMPLETED	Evaluation of Stress Disorders
NCT00118014	PHASE4	COMPLETED	Sertraline and Habit Reversal in the Treatment of Patients With Trichotillomania
NCT00159965	PHASE4	COMPLETED	Treatments for Psychogenic Nonepileptic Seizures (NES)
NCT00177424	PHASE4	TERMINATED	Sertraline for Preventing Post-stroke Depression and Improving Rehabilitation Outcomes
NCT00177996	PHASE4	COMPLETED	Pharmacotherapy in Depression With Panic Spectrum
NCT00178828	PHASE4	COMPLETED	Dynamic Measures of Neurochemistry in Mood Disorders
NCT00182078	PHASE4	COMPLETED	A Study of Sertraline to Prevent PTSD
NCT00182533	PHASE4	TERMINATED	Sertraline in Generalized Social Phobia With Co-Occurring Anxiety and Mood Disorders
NCT00198094	PHASE4	COMPLETED	A Study of Sertraline and Early Alprazolam XR Administration Versus Sertraline Only in Panic Disorder Patients
NCT00208702	PHASE4	COMPLETED	Thyroid Medication and Antidepressants for Treating Major Depression
NCT00229476	PHASE4	COMPLETED	Study of Medication and Placebo Response in Major Depression
NCT00234312	PHASE4	COMPLETED	Medications for the Treatment of Dysthymic Disorder and Double Depression
NCT00282828	PHASE4	COMPLETED	Improving Treatment Outcomes in Pharmacotherapy of Generalized Social Anxiety Disorder
NCT00318773	PHASE4	COMPLETED	Short-Term Versus Long-Term Treatment for Severe Premenstrual Syndrome (PMS)
NCT00368550	PHASE4	COMPLETED	Sertraline Pharmacotherapy for Alcoholism Subtypes
NCT00374426	PHASE4	COMPLETED	Preventing Depression Recurrence in Diabetes
NCT00375843	PHASE4	COMPLETED	Brain Activity Changes and Treatment Response in Depressed People Who Are Receiving Antidepressant Medication
NCT00391430	PHASE4	TERMINATED	Cognitive Behavioral Therapy Versus Sertraline in the Treatment of Post-Traumatic Stress Disorder
NCT00485862	PHASE4	COMPLETED	Combination Therapy in Patients With Depression
NCT00508859	PHASE4	COMPLETED	Maintenance Study for Adolescent Depression
NCT00536198	PHASE4	COMPLETED	Evaluating the Effectiveness of Sertraline in Treating Women With Premenstrual Dysphoric Disorder
NCT00594269	PHASE4	COMPLETED	Dementia Antipsychotics And Antidepressants Discontinuation Study
NCT00624013	PHASE4	COMPLETED	Treatment of Diabetes and Depression in Hispanics and African Americans and Its Effect on A1c and Quality of Life.
NCT00644982	PHASE4	COMPLETED	A Comparison of Sertraline Versus Venlafaxine XR in the Treatment of Major Depression
NCT00666757	PHASE4	COMPLETED	A Study Comparing Duloxetine to Other Antidepressants in the Treatment of Severe Depression
NCT00677352	PHASE4	COMPLETED	A Study Of Sertraline Compared With Paroxetine In The Treatment Of Panic Disorder
NCT00680602	PHASE4	COMPLETED	Group Cognitive Behavioral Therapy Versus Fluoxetine for Obsessive-Compulsive Disorder: a Practical Trial
NCT00693849	PHASE4	UNKNOWN	International Study to Predict Optimised Treatment - in Depression
NCT00744328	PHASE4	TERMINATED	Postpartum Depression: Transdermal Estradiol Versus Sertraline
NCT00834652	PHASE4	COMPLETED	Adding an Insulin-Sensitizing Medication to Depression Treatment for People Who Are Depressed and Overweight
NCT00835627	PHASE4	COMPLETED	Treatment Trial for Psychogenic Nonepileptic Seizures
NCT00917397	PHASE4	COMPLETED	The Outcome of Treatment of Traumatised Refugees With Psychotherapy and/or Antidepressants
NCT00955474	PHASE4	TERMINATED	Seroquel Alone Versus Seroquel With an SSRI for Depression With Psychotic Symptoms
NCT00969852	PHASE4	COMPLETED	Pharmacokinetics and Pharmacodynamics of Sertraline After Low Dose Administration
NCT01109693	PHASE4	COMPLETED	Strategic Use of New Generation Antidepressants for Depression
NCT01114100	PHASE4	COMPLETED	The Effects of Treatment With Sertraline for Noncardiac Chest Pain
NCT01178671	PHASE4	COMPLETED	Combined Mirtazapine and SSRI Treatment of PTSD: A Placebo-Controlled Trial
NCT01287494	PHASE4	UNKNOWN	Depression Care Management for Depressed Elders in China Primary Care
NCT01309074	PHASE4	WITHDRAWN	Does Pregabalin Improve Symptoms of Anxiety in Patients With Epilepsy? A Comparison With Sertraline
NCT01427608	PHASE4	COMPLETED	Sustaining Remission of Psychotic Depression
NCT01524133	PHASE4	COMPLETED	PROlonGed ExpoSure Sertraline
NCT01569685	PHASE4	COMPLETED	The Treatment of Traumatised Refugees With Sertraline Versus Venlafaxine in Combination With Psychotherapy
NCT01764867	PHASE4	UNKNOWN	Algorithm Guided Treatment Strategies for Major Depressive Disorder
NCT01794455	PHASE4	TERMINATED	Effects of Cerebral Hypoperfusion and Its Reversal on Late-Life Depression
NCT01856127	PHASE4	TERMINATED	Does Vilazodone Help With Antidepressant-associated Sexual Dysfunction?
NCT01896934	PHASE4	COMPLETED	Frontal Hypoperfusion Effects on Antidepressant Outcomes in Late-Life Depression
NCT02022709	PHASE4	COMPLETED	Efficacy of Exposure and Response Prevention(ERP) and SSRIs in Chinese OCD Patients
NCT02228005	PHASE4	COMPLETED	The Effect of a Selective Serotonin Reuptake Inhibitor on Gait, Balance, and Bone Metabolism in Older Adults
NCT02237937	PHASE4	UNKNOWN	Optimizing Antidepressant Treatment by Genotype-dependent Adjustment of Medication According to the ABCB1 Gene
NCT02268487	PHASE4	UNKNOWN	Integral Assessment in Unipolar Depression
NCT02347033	PHASE4	TERMINATED	Trial of Sertraline Versus Cognitive Behaviour Therapy for Generalised Anxiety
NCT02463110	PHASE4	TERMINATED	Acute Myocardial Necrosis and Depression: Antiplatelet Effect of Reuptake Inhibition of Serotonin
NCT02504931	PHASE4	COMPLETED	Serotonin Selective Reuptake Inhibitor Treatment of Dual Diagnosis Post-traumatic Stress Disorder and Alcohol Problems
NCT02520726	PHASE4	TERMINATED	PTSD Prevention Study Examining the Efficacy of Sertraline in Burn Victims
NCT02641652	PHASE4	UNKNOWN	A Randomized Controlled Trial of Sertraline in Paroxysmal Arterial Hypertension
NCT02777372	PHASE4	COMPLETED	Stress & Premenstrual Symptoms Study
NCT02901249	PHASE4	COMPLETED	Cost- Effectiveness and Quality of Life Assessment in Major Depression Disorder
NCT02918097	PHASE4	COMPLETED	Cost- Effectiveness and Quality of Life Assessment in Bipolar Disorder Depressive Episode
NCT03068429	PHASE4	COMPLETED	Fear Conditioned Response in Healthy Subjects and in OCD Patients Pre and Post Treatment With Sertraline.
NCT03779789	PHASE4	COMPLETED	Vortioxetine in the Elderly vs. Selective Serotonin Reuptake Inhibitors (SSRIs): a Pragmatic Assessment
NCT03978286	PHASE4	COMPLETED	Vortioxetine vs Sertraline in Mexicans
NCT04094870	PHASE4	COMPLETED	A Pilot Trial of Perinatal Depression Treatment in HIV Infected Women
NCT04183205	PHASE4	TERMINATED	Predicting SSRI Efficacy in Veterans With PTSD
NCT04388202	PHASE4	WITHDRAWN	Leveraging EEG for Antidepressant Prediction With Sertraline and Escitalopram
NCT04963257	PHASE4	UNKNOWN	Sertraline Combined With Fluvoxamine in the Treatment of Refractory Obsessive-compulsive Disorder
NCT05537584	PHASE4	COMPLETED	SMART Trial to Predict Anhedonia Response to Antidepressant Treatment
NCT06124417	PHASE4	COMPLETED	Efficacy and Safety of Sertraline in the Treatment of Maintenance Hemodialysis Patients With Depression
NCT06357104	PHASE4	COMPLETED	Detoxification From the Lipid Tract
NCT05603104	PHASE3	RECRUITING	Intensified Pharmacological Treatment for Schizophrenia, Major Depressive Disorder and Bipolar Depression After a First-time Treatment Failure
NCT05973786	PHASE3	RECRUITING	The Effect of a Six Week Intensified Pharmacological Treatment for Bipolar Depression Compared to Treatment as Usual in Subjects Who Had a First-time Treatment Failure on Their First-line Treatment.
NCT06698666	PHASE3	RECRUITING	Efficacy of Statins Among Major Depressive Disorder
NCT06827431	PHASE3	NOT_YET_RECRUITING	The Research of Ammoxetine Hydrochloride Enteric-coated Tablets in Subjects With Depression
NCT07574060	PHASE2/PHASE3	NOT_YET_RECRUITING	Allopurinol in Depression
NCT00000384	PHASE3	COMPLETED	Treatment of Obsessive-Compulsive Disorder (OCD) in Children
NCT00026637	PHASE3	COMPLETED	Depression and Health Outcomes in Refractory Epilepsy
NCT00043550	PHASE3	COMPLETED	Treatments for Depression: Drug Versus Psychotherapy
NCT00052078	PHASE3	COMPLETED	Child and Adolescent Anxiety Disorders (CAMS)
NCT00056472	PHASE3	COMPLETED	Study of Pharmacotherapy of Psychotic Depression
NCT00078286	PHASE2/PHASE3	COMPLETED	Antidepressant Medication Treatment for Depression in Individuals With Chronic Heart Failure
NCT00078767	PHASE3	COMPLETED	Pharmacologic Treatment of PTSD in Sexually Abused Children
NCT00080158	PHASE2/PHASE3	COMPLETED	Treatment of Adolescent Suicide Attempters (TASA)
NCT00086138	PHASE2/PHASE3	COMPLETED	Depression in Alzheimer’s Disease-2
NCT00116857	PHASE3	COMPLETED	Omega-3 Fatty Acids to Improve Depression and Reduce Cardiovascular Risk Factors
NCT00118417	PHASE2/PHASE3	COMPLETED	Therapies for Treatment-Resistant Panic Disorder Symptoms
NCT00127673	PHASE3	COMPLETED	Comparison of Two Treatments for Post-Traumatic Stress Disorder
NCT00158990	PHASE3	COMPLETED	Triiodothyronine (T3) Supplementation in the Treatment of Bipolar and Unipolar Depression.
NCT00179257	PHASE3	COMPLETED	The Effectiveness of Sertraline in Patients Who Have Had Inadequate Response to Escitalopram
NCT00179283	PHASE3	COMPLETED	Sertraline vs. Venlafaxine XR
NCT00215241	PHASE2/PHASE3	COMPLETED	Risperidone Augmentation for PTSD
NCT00232167	PHASE3	TERMINATED	Study Of Indiplon/Placebo With Sertraline In Insomnia Co-Existing With Depression
NCT00276900	PHASE3	COMPLETED	Sertraline for the Prevention of Recurrent Postpartum Depression
NCT00276965	PHASE3	COMPLETED	Bipolar II Depression: Lithium, SSRI, or the Combination

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

PharmGKB dosing guidelines (5) — CPIC / DPWG genotype-guided dosing for this drug (drug × pharmacogene):

Guideline	Source	Gene(s)	Dosing	Recommendation
Annotation of DPWG Guideline for sertraline and CYP2C19	DPWG	CYP2C19	yes	yes
Annotation of CPIC Guideline for sertraline and CYP2B6, CYP2C19	CPIC	CYP2B6;CYP2C19	yes	yes
Annotation of DPWG Guideline for sertraline and CYP2D6	DPWG	CYP2D6
Annotation of CPIC Guideline for desvenlafaxine, duloxetine, fluoxetin	CPIC	HTR2A
Annotation of CPIC Guideline for citalopram, desvenlafaxine, duloxetin	CPIC	SLC6A4

PharmGKB also curates 22 clinical and 140 variant annotation(s) for this drug (gene-keyed; see PharmGKB).

Related molecules

Related molecules

Molecules sharing ≥1 of this drug’s curated primary targets, merged from two biobtree sources and ranked by shared-target count, then clinical phase: ChEMBL clinical-stage candidates (development phase ≥2) and PubChem drug-class bioactivity (approved / known drugs acting on the target). Deduplicated by drug name; the drug’s own salt forms are excluded. Note: for a drug with few primary targets a shared-target match can reflect off-target / promiscuous binding rather than the same therapeutic mechanism — the phase ordering surfaces bona-fide therapeutics first.

441 molecules share ≥1 primary target. Top 100 by shared-target count:

Molecule	Source	Status	Shared targets
CRIZOTINIB	ChEMBL + PubChem	Phase 4 (approved)	SLC6A4
GENTIAN VIOLET	ChEMBL + PubChem	Phase 4 (approved)	SLC6A4
OLODATEROL	ChEMBL + PubChem	Phase 4 (approved)	SLC6A4
TADALAFIL	ChEMBL + PubChem	Phase 4 (approved)	SLC6A4
TAFENOQUINE	ChEMBL + PubChem	Phase 4 (approved)	SLC6A4
UMECLIDINIUM	ChEMBL + PubChem	Phase 4 (approved)	SLC6A4
ACETOPHENAZINE	ChEMBL	Phase 4 (approved)	SLC6A4
ACRIVASTINE	ChEMBL	Phase 4 (approved)	SLC6A4
ALECTINIB	ChEMBL	Phase 4 (approved)	SLC6A4
ALLOPURINOL	ChEMBL	Phase 4 (approved)	SLC6A4
AMBENONIUM	ChEMBL	Phase 4 (approved)	SLC6A4
AMIODARONE	ChEMBL	Phase 4 (approved)	SLC6A4
AMITRIPTYLINE	ChEMBL	Phase 4 (approved)	SLC6A4
AMOXAPINE	ChEMBL	Phase 4 (approved)	SLC6A4
AMPHOTERICIN B	ChEMBL	Phase 4 (approved)	SLC6A4
APOMORPHINE	ChEMBL	Phase 4 (approved)	SLC6A4
ARFORMOTEROL	ChEMBL	Phase 4 (approved)	SLC6A4
ARIPIPRAZOLE	ChEMBL	Phase 4 (approved)	SLC6A4
ASENAPINE	ChEMBL	Phase 4 (approved)	SLC6A4
ASTEMIZOLE	ChEMBL	Phase 4 (approved)	SLC6A4
ATOMOXETINE	ChEMBL	Phase 4 (approved)	SLC6A4
ATRACURIUM	ChEMBL	Phase 4 (approved)	SLC6A4
AZATHIOPRINE	ChEMBL	Phase 4 (approved)	SLC6A4
AZELASTINE	ChEMBL	Phase 4 (approved)	SLC6A4
BALSALAZIDE	ChEMBL	Phase 4 (approved)	SLC6A4
BAZEDOXIFENE	ChEMBL	Phase 4 (approved)	SLC6A4
BENFLUOREX	ChEMBL	Phase 4 (approved)	SLC6A4
BENZPHETAMINE	ChEMBL	Phase 4 (approved)	SLC6A4
BENZTROPINE	ChEMBL	Phase 4 (approved)	SLC6A4
BENZYDAMINE	ChEMBL	Phase 4 (approved)	SLC6A4
BEPRIDIL	ChEMBL	Phase 4 (approved)	SLC6A4
BOSUTINIB	ChEMBL	Phase 4 (approved)	SLC6A4
BREXPIPRAZOLE	ChEMBL	Phase 4 (approved)	SLC6A4
BROMHEXINE	ChEMBL	Phase 4 (approved)	SLC6A4
BROMODIPHENHYDRAMINE	ChEMBL	Phase 4 (approved)	SLC6A4
BROMPERIDOL	ChEMBL	Phase 4 (approved)	SLC6A4
BROMPHENIRAMINE	ChEMBL	Phase 4 (approved)	SLC6A4
BUPROPION	ChEMBL	Phase 4 (approved)	SLC6A4
BUTENAFINE	ChEMBL	Phase 4 (approved)	SLC6A4
CABERGOLINE	ChEMBL	Phase 4 (approved)	SLC6A4
CALCIPOTRIENE	ChEMBL	Phase 4 (approved)	SLC6A4
CALCITRIOL	ChEMBL	Phase 4 (approved)	SLC6A4
CANAGLIFLOZIN	ChEMBL	Phase 4 (approved)	SLC6A4
CARBINOXAMINE	ChEMBL	Phase 4 (approved)	SLC6A4
CARIPRAZINE	ChEMBL	Phase 4 (approved)	SLC6A4
CARVEDILOL	ChEMBL	Phase 4 (approved)	SLC6A4
CEFONICID	ChEMBL	Phase 4 (approved)	SLC6A4
CELECOXIB	ChEMBL	Phase 4 (approved)	SLC6A4
CETIRIZINE	ChEMBL	Phase 4 (approved)	SLC6A4
CHLORHEXIDINE	ChEMBL	Phase 4 (approved)	SLC6A4
CHLORPHENIRAMINE	ChEMBL	Phase 4 (approved)	SLC6A4
CHLORPHENTERMINE	ChEMBL	Phase 4 (approved)	SLC6A4
CHLORPROMAZINE	ChEMBL	Phase 4 (approved)	SLC6A4
CHLORPROTHIXENE	ChEMBL	Phase 4 (approved)	SLC6A4
CINACALCET	ChEMBL	Phase 4 (approved)	SLC6A4
CINNARIZINE	ChEMBL	Phase 4 (approved)	SLC6A4
CISAPRIDE	ChEMBL	Phase 4 (approved)	SLC6A4
CITALOPRAM	ChEMBL	Phase 4 (approved)	SLC6A4
CLEMASTINE	ChEMBL	Phase 4 (approved)	SLC6A4
CLIDINIUM	ChEMBL	Phase 4 (approved)	SLC6A4
CLOBUTINOL	ChEMBL	Phase 4 (approved)	SLC6A4
CLOFAZIMINE	ChEMBL	Phase 4 (approved)	SLC6A4
CLOMIPHENE	ChEMBL	Phase 4 (approved)	SLC6A4
CLOMIPRAMINE	ChEMBL	Phase 4 (approved)	SLC6A4
CLOPIDOGREL	ChEMBL	Phase 4 (approved)	SLC6A4
CLOTRIMAZOLE	ChEMBL	Phase 4 (approved)	SLC6A4
CLOZAPINE	ChEMBL	Phase 4 (approved)	SLC6A4
COBIMETINIB	ChEMBL	Phase 4 (approved)	SLC6A4
COCAINE	ChEMBL	Phase 4 (approved)	SLC6A4
CYCLOBENZAPRINE	ChEMBL	Phase 4 (approved)	SLC6A4
CYPROHEPTADINE	ChEMBL	Phase 4 (approved)	SLC6A4
DANAZOL	ChEMBL	Phase 4 (approved)	SLC6A4
DAPIPRAZOLE	ChEMBL	Phase 4 (approved)	SLC6A4
DARIFENACIN	ChEMBL	Phase 4 (approved)	SLC6A4
DAUNORUBICIN	ChEMBL	Phase 4 (approved)	SLC6A4
DELAMANID	ChEMBL	Phase 4 (approved)	SLC6A4
DEQUALINIUM	ChEMBL	Phase 4 (approved)	SLC6A4
DESIPRAMINE	ChEMBL	Phase 4 (approved)	SLC6A4
DESLORATADINE	ChEMBL	Phase 4 (approved)	SLC6A4
DESOGESTREL	ChEMBL	Phase 4 (approved)	SLC6A4
DESVENLAFAXINE	ChEMBL	Phase 4 (approved)	SLC6A4
DEXBROMPHENIRAMINE	ChEMBL	Phase 4 (approved)	SLC6A4
DEXCHLORPHENIRAMINE	ChEMBL	Phase 4 (approved)	SLC6A4
DEXTROAMPHETAMINE	ChEMBL	Phase 4 (approved)	SLC6A4
DEXTROMETHORPHAN	ChEMBL	Phase 4 (approved)	SLC6A4
DIBENZEPIN	ChEMBL	Phase 4 (approved)	SLC6A4
DIETHYLSTILBESTROL	ChEMBL	Phase 4 (approved)	SLC6A4
DIPHENHYDRAMINE	ChEMBL	Phase 4 (approved)	SLC6A4
DOBUTAMINE	ChEMBL	Phase 4 (approved)	SLC6A4
DOLASETRON	ChEMBL	Phase 4 (approved)	SLC6A4
DOMPERIDONE	ChEMBL	Phase 4 (approved)	SLC6A4
DOTHIEPIN	ChEMBL	Phase 4 (approved)	SLC6A4
DOXAZOSIN	ChEMBL	Phase 4 (approved)	SLC6A4
DOXEPIN	ChEMBL	Phase 4 (approved)	SLC6A4
DRONEDARONE	ChEMBL	Phase 4 (approved)	SLC6A4
DULOXETINE	ChEMBL	Phase 4 (approved)	SLC6A4
EBASTINE	ChEMBL	Phase 4 (approved)	SLC6A4
ECONAZOLE	ChEMBL	Phase 4 (approved)	SLC6A4
EPALRESTAT	ChEMBL	Phase 4 (approved)	SLC6A4
EPINASTINE	ChEMBL	Phase 4 (approved)	SLC6A4